Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -77.09% | -63.56% | -95.24% | -91.64% | -89.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.09% | -63.56% | -95.24% | -91.64% | -89.34% |
| Cost of Revenue | 53.56% | -31.41% | -80.73% | -78.00% | -61.73% |
| Gross Profit | -84.91% | 25.66% | 6.37% | 44.02% | -1.05% |
| SG&A Expenses | 67.37% | 38.74% | 13.27% | -8.09% | -25.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.85% | 4.33% | -38.92% | -50.09% | -47.14% |
| Operating Income | -74.34% | -9.68% | -7.24% | 21.67% | 21.70% |
| Income Before Tax | -11.05% | 75.97% | -46.36% | -383.70% | 24.26% |
| Income Tax Expenses | 714.29% | -129.03% | -53.57% | -50.00% | -48.15% |
| Earnings from Continuing Operations | -11.37% | 76.02% | -46.25% | -383.32% | 24.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.37% | 76.02% | -46.25% | -383.32% | 24.28% |
| EBIT | -74.34% | -9.68% | -7.24% | 21.67% | 21.70% |
| EBITDA | -74.80% | -9.75% | -7.25% | 21.89% | 21.80% |
| EPS Basic | 91.31% | 93.59% | 86.82% | 70.27% | 64.12% |
| Normalized Basic EPS | 72.32% | 82.92% | 73.28% | 59.94% | 56.79% |
| EPS Diluted | 89.05% | 90.58% | 83.91% | 68.83% | 63.17% |
| Normalized Diluted EPS | 71.79% | 82.60% | 73.28% | 59.94% | 56.79% |
| Average Basic Shares Outstanding | 3,508.12% | 8,868.64% | 13,511.64% | 1,053.09% | 607.01% |
| Average Diluted Shares Outstanding | 3,980.28% | 10,403.72% | 13,511.64% | 1,053.09% | 607.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |